Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q14390

UPID:
GGTL2_HUMAN

ALTERNATIVE NAMES:
Gamma-glutamyltransferase light chain 2; Gamma-glutamyltransferase-like protein 4

ALTERNATIVE UPACC:
Q14390; A1A516; A2VCM9; Q5NV76; Q6ISH0

BACKGROUND:
The enzyme Glutathione hydrolase light chain 2, with alternative names Gamma-glutamyltransferase light chain 2 and Gamma-glutamyltransferase-like protein 4, is integral to the glutathione metabolism pathway. It facilitates the cleavage of glutathione in response to oxidative stress, playing a vital role in protecting cells from damage. This enzyme's activity is essential for the detoxification of harmful substances and the maintenance of cellular redox balance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Glutathione hydrolase light chain 2 offers promising avenues for therapeutic intervention. Its critical role in managing oxidative stress and detoxifying harmful compounds makes it a compelling target for the development of novel treatments aimed at bolstering cellular resilience and combating diseases linked to oxidative damage.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.